Roth MKM Reiterates Buy on Bio-Path Hldgs, Maintains $40 Price Target
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst Philip Shen has reiterated a Buy rating on Bio-Path Holdings (BPTH) and maintained a $40 price target. This reaffirms the firm's positive outlook on the company's stock.
April 18, 2024 | 5:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roth MKM analyst Philip Shen reiterates a Buy rating on Bio-Path Holdings, maintaining a $40 price target, indicating a strong positive outlook.
The reiteration of a Buy rating and the maintenance of a $40 price target by a reputable analyst like Philip Shen suggests a strong conviction in the future performance of Bio-Path Holdings. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100